Found 6 hits for monomerid = 50017339 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
cAMP-specific 3',5'-cyclic phosphodiesterase 4B
(Homo sapiens (Human)) | BDBM50017339
(CHEMBL3288028)Show SMILES Cc1cc(nn1C)C(=O)N[C@H]1CC[C@H](CC1)NC(=O)c1cc(F)cnc1Oc1cccc(c1)-c1ccc(CCN2CCC(CC2)N2CCCC2)cc1 |r,wU:10.10,13.17,(20.81,-18.66,;20.38,-20.13,;18.93,-20.66,;18.98,-22.18,;20.46,-22.63,;21.33,-21.35,;22.87,-21.3,;17.76,-23.13,;17.76,-24.67,;16.43,-22.36,;15.08,-23.13,;15.08,-24.67,;13.75,-25.44,;12.41,-24.67,;12.4,-23.13,;13.74,-22.36,;11.08,-25.44,;9.74,-24.68,;9.73,-23.14,;8.41,-25.45,;7.07,-24.69,;5.73,-25.46,;4.4,-24.69,;5.73,-27.01,;7.07,-27.78,;8.41,-27.01,;9.75,-27.78,;9.75,-29.32,;8.41,-30.09,;8.42,-31.63,;9.75,-32.4,;11.09,-31.62,;11.08,-30.08,;12.43,-32.38,;12.43,-33.93,;13.77,-34.69,;15.1,-33.91,;16.44,-34.67,;17.77,-33.9,;19.1,-34.66,;19.1,-36.19,;20.42,-36.95,;21.75,-36.19,;21.75,-34.65,;20.41,-33.88,;23.08,-36.95,;23.24,-38.48,;24.74,-38.8,;25.51,-37.46,;24.47,-36.33,;15.09,-32.36,;13.75,-31.6,)| Show InChI InChI=1S/C41H50FN7O3/c1-28-24-38(46-47(28)2)40(51)45-34-14-12-33(13-15-34)44-39(50)37-26-32(42)27-43-41(37)52-36-7-5-6-31(25-36)30-10-8-29(9-11-30)16-21-48-22-17-35(18-23-48)49-19-3-4-20-49/h5-11,24-27,33-35H,3-4,12-23H2,1-2H3,(H,44,50)(H,45,51)/t33-,34+ | PDB
UniProtKB/SwissProt
UniProtKB/TrEMBL
antibodypedia
GoogleScholar
AffyNet 
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 0.0398 | n/a | n/a | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Inhibition of human recombinant PDE4B using [3H]cAMP by packard topcount scintillation counting analysis |
J Med Chem 57: 4661-76 (2014)
Article DOI: 10.1021/jm5001216
BindingDB Entry DOI: 10.7270/Q2708302 |
More data for this
Ligand-Target Pair | |
Cytochrome P450 3A4
(Homo sapiens (Human)) | BDBM50017339
(CHEMBL3288028)Show SMILES Cc1cc(nn1C)C(=O)N[C@H]1CC[C@H](CC1)NC(=O)c1cc(F)cnc1Oc1cccc(c1)-c1ccc(CCN2CCC(CC2)N2CCCC2)cc1 |r,wU:10.10,13.17,(20.81,-18.66,;20.38,-20.13,;18.93,-20.66,;18.98,-22.18,;20.46,-22.63,;21.33,-21.35,;22.87,-21.3,;17.76,-23.13,;17.76,-24.67,;16.43,-22.36,;15.08,-23.13,;15.08,-24.67,;13.75,-25.44,;12.41,-24.67,;12.4,-23.13,;13.74,-22.36,;11.08,-25.44,;9.74,-24.68,;9.73,-23.14,;8.41,-25.45,;7.07,-24.69,;5.73,-25.46,;4.4,-24.69,;5.73,-27.01,;7.07,-27.78,;8.41,-27.01,;9.75,-27.78,;9.75,-29.32,;8.41,-30.09,;8.42,-31.63,;9.75,-32.4,;11.09,-31.62,;11.08,-30.08,;12.43,-32.38,;12.43,-33.93,;13.77,-34.69,;15.1,-33.91,;16.44,-34.67,;17.77,-33.9,;19.1,-34.66,;19.1,-36.19,;20.42,-36.95,;21.75,-36.19,;21.75,-34.65,;20.41,-33.88,;23.08,-36.95,;23.24,-38.48,;24.74,-38.8,;25.51,-37.46,;24.47,-36.33,;15.09,-32.36,;13.75,-31.6,)| Show InChI InChI=1S/C41H50FN7O3/c1-28-24-38(46-47(28)2)40(51)45-34-14-12-33(13-15-34)44-39(50)37-26-32(42)27-43-41(37)52-36-7-5-6-31(25-36)30-10-8-29(9-11-30)16-21-48-22-17-35(18-23-48)49-19-3-4-20-49/h5-11,24-27,33-35H,3-4,12-23H2,1-2H3,(H,44,50)(H,45,51)/t33-,34+ | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
UniProtKB/TrEMBL
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Inhibition of CYP3A4 (unknown origin) |
J Med Chem 57: 4661-76 (2014)
Article DOI: 10.1021/jm5001216
BindingDB Entry DOI: 10.7270/Q2708302 |
More data for this
Ligand-Target Pair | |
Cytochrome P450 2C19
(Homo sapiens (Human)) | BDBM50017339
(CHEMBL3288028)Show SMILES Cc1cc(nn1C)C(=O)N[C@H]1CC[C@H](CC1)NC(=O)c1cc(F)cnc1Oc1cccc(c1)-c1ccc(CCN2CCC(CC2)N2CCCC2)cc1 |r,wU:10.10,13.17,(20.81,-18.66,;20.38,-20.13,;18.93,-20.66,;18.98,-22.18,;20.46,-22.63,;21.33,-21.35,;22.87,-21.3,;17.76,-23.13,;17.76,-24.67,;16.43,-22.36,;15.08,-23.13,;15.08,-24.67,;13.75,-25.44,;12.41,-24.67,;12.4,-23.13,;13.74,-22.36,;11.08,-25.44,;9.74,-24.68,;9.73,-23.14,;8.41,-25.45,;7.07,-24.69,;5.73,-25.46,;4.4,-24.69,;5.73,-27.01,;7.07,-27.78,;8.41,-27.01,;9.75,-27.78,;9.75,-29.32,;8.41,-30.09,;8.42,-31.63,;9.75,-32.4,;11.09,-31.62,;11.08,-30.08,;12.43,-32.38,;12.43,-33.93,;13.77,-34.69,;15.1,-33.91,;16.44,-34.67,;17.77,-33.9,;19.1,-34.66,;19.1,-36.19,;20.42,-36.95,;21.75,-36.19,;21.75,-34.65,;20.41,-33.88,;23.08,-36.95,;23.24,-38.48,;24.74,-38.8,;25.51,-37.46,;24.47,-36.33,;15.09,-32.36,;13.75,-31.6,)| Show InChI InChI=1S/C41H50FN7O3/c1-28-24-38(46-47(28)2)40(51)45-34-14-12-33(13-15-34)44-39(50)37-26-32(42)27-43-41(37)52-36-7-5-6-31(25-36)30-10-8-29(9-11-30)16-21-48-22-17-35(18-23-48)49-19-3-4-20-49/h5-11,24-27,33-35H,3-4,12-23H2,1-2H3,(H,44,50)(H,45,51)/t33-,34+ | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Inhibition of CYP2C19 (unknown origin) |
J Med Chem 57: 4661-76 (2014)
Article DOI: 10.1021/jm5001216
BindingDB Entry DOI: 10.7270/Q2708302 |
More data for this
Ligand-Target Pair | |
Cytochrome P450 2D6
(Homo sapiens (Human)) | BDBM50017339
(CHEMBL3288028)Show SMILES Cc1cc(nn1C)C(=O)N[C@H]1CC[C@H](CC1)NC(=O)c1cc(F)cnc1Oc1cccc(c1)-c1ccc(CCN2CCC(CC2)N2CCCC2)cc1 |r,wU:10.10,13.17,(20.81,-18.66,;20.38,-20.13,;18.93,-20.66,;18.98,-22.18,;20.46,-22.63,;21.33,-21.35,;22.87,-21.3,;17.76,-23.13,;17.76,-24.67,;16.43,-22.36,;15.08,-23.13,;15.08,-24.67,;13.75,-25.44,;12.41,-24.67,;12.4,-23.13,;13.74,-22.36,;11.08,-25.44,;9.74,-24.68,;9.73,-23.14,;8.41,-25.45,;7.07,-24.69,;5.73,-25.46,;4.4,-24.69,;5.73,-27.01,;7.07,-27.78,;8.41,-27.01,;9.75,-27.78,;9.75,-29.32,;8.41,-30.09,;8.42,-31.63,;9.75,-32.4,;11.09,-31.62,;11.08,-30.08,;12.43,-32.38,;12.43,-33.93,;13.77,-34.69,;15.1,-33.91,;16.44,-34.67,;17.77,-33.9,;19.1,-34.66,;19.1,-36.19,;20.42,-36.95,;21.75,-36.19,;21.75,-34.65,;20.41,-33.88,;23.08,-36.95,;23.24,-38.48,;24.74,-38.8,;25.51,-37.46,;24.47,-36.33,;15.09,-32.36,;13.75,-31.6,)| Show InChI InChI=1S/C41H50FN7O3/c1-28-24-38(46-47(28)2)40(51)45-34-14-12-33(13-15-34)44-39(50)37-26-32(42)27-43-41(37)52-36-7-5-6-31(25-36)30-10-8-29(9-11-30)16-21-48-22-17-35(18-23-48)49-19-3-4-20-49/h5-11,24-27,33-35H,3-4,12-23H2,1-2H3,(H,44,50)(H,45,51)/t33-,34+ | PDB
UniProtKB/SwissProt
UniProtKB/TrEMBL
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Inhibition of CYP2D6 (unknown origin) |
J Med Chem 57: 4661-76 (2014)
Article DOI: 10.1021/jm5001216
BindingDB Entry DOI: 10.7270/Q2708302 |
More data for this
Ligand-Target Pair | |
Cytochrome P450 1A
(Homo sapiens (Human)) | BDBM50017339
(CHEMBL3288028)Show SMILES Cc1cc(nn1C)C(=O)N[C@H]1CC[C@H](CC1)NC(=O)c1cc(F)cnc1Oc1cccc(c1)-c1ccc(CCN2CCC(CC2)N2CCCC2)cc1 |r,wU:10.10,13.17,(20.81,-18.66,;20.38,-20.13,;18.93,-20.66,;18.98,-22.18,;20.46,-22.63,;21.33,-21.35,;22.87,-21.3,;17.76,-23.13,;17.76,-24.67,;16.43,-22.36,;15.08,-23.13,;15.08,-24.67,;13.75,-25.44,;12.41,-24.67,;12.4,-23.13,;13.74,-22.36,;11.08,-25.44,;9.74,-24.68,;9.73,-23.14,;8.41,-25.45,;7.07,-24.69,;5.73,-25.46,;4.4,-24.69,;5.73,-27.01,;7.07,-27.78,;8.41,-27.01,;9.75,-27.78,;9.75,-29.32,;8.41,-30.09,;8.42,-31.63,;9.75,-32.4,;11.09,-31.62,;11.08,-30.08,;12.43,-32.38,;12.43,-33.93,;13.77,-34.69,;15.1,-33.91,;16.44,-34.67,;17.77,-33.9,;19.1,-34.66,;19.1,-36.19,;20.42,-36.95,;21.75,-36.19,;21.75,-34.65,;20.41,-33.88,;23.08,-36.95,;23.24,-38.48,;24.74,-38.8,;25.51,-37.46,;24.47,-36.33,;15.09,-32.36,;13.75,-31.6,)| Show InChI InChI=1S/C41H50FN7O3/c1-28-24-38(46-47(28)2)40(51)45-34-14-12-33(13-15-34)44-39(50)37-26-32(42)27-43-41(37)52-36-7-5-6-31(25-36)30-10-8-29(9-11-30)16-21-48-22-17-35(18-23-48)49-19-3-4-20-49/h5-11,24-27,33-35H,3-4,12-23H2,1-2H3,(H,44,50)(H,45,51)/t33-,34+ | PDB
MMDB
Reactome pathway
KEGG
B.MOAD
DrugBank
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Inhibition of CYP1A2 (unknown origin) |
J Med Chem 57: 4661-76 (2014)
Article DOI: 10.1021/jm5001216
BindingDB Entry DOI: 10.7270/Q2708302 |
More data for this
Ligand-Target Pair | |
Cytochrome P450 2C9
(Homo sapiens (Human)) | BDBM50017339
(CHEMBL3288028)Show SMILES Cc1cc(nn1C)C(=O)N[C@H]1CC[C@H](CC1)NC(=O)c1cc(F)cnc1Oc1cccc(c1)-c1ccc(CCN2CCC(CC2)N2CCCC2)cc1 |r,wU:10.10,13.17,(20.81,-18.66,;20.38,-20.13,;18.93,-20.66,;18.98,-22.18,;20.46,-22.63,;21.33,-21.35,;22.87,-21.3,;17.76,-23.13,;17.76,-24.67,;16.43,-22.36,;15.08,-23.13,;15.08,-24.67,;13.75,-25.44,;12.41,-24.67,;12.4,-23.13,;13.74,-22.36,;11.08,-25.44,;9.74,-24.68,;9.73,-23.14,;8.41,-25.45,;7.07,-24.69,;5.73,-25.46,;4.4,-24.69,;5.73,-27.01,;7.07,-27.78,;8.41,-27.01,;9.75,-27.78,;9.75,-29.32,;8.41,-30.09,;8.42,-31.63,;9.75,-32.4,;11.09,-31.62,;11.08,-30.08,;12.43,-32.38,;12.43,-33.93,;13.77,-34.69,;15.1,-33.91,;16.44,-34.67,;17.77,-33.9,;19.1,-34.66,;19.1,-36.19,;20.42,-36.95,;21.75,-36.19,;21.75,-34.65,;20.41,-33.88,;23.08,-36.95,;23.24,-38.48,;24.74,-38.8,;25.51,-37.46,;24.47,-36.33,;15.09,-32.36,;13.75,-31.6,)| Show InChI InChI=1S/C41H50FN7O3/c1-28-24-38(46-47(28)2)40(51)45-34-14-12-33(13-15-34)44-39(50)37-26-32(42)27-43-41(37)52-36-7-5-6-31(25-36)30-10-8-29(9-11-30)16-21-48-22-17-35(18-23-48)49-19-3-4-20-49/h5-11,24-27,33-35H,3-4,12-23H2,1-2H3,(H,44,50)(H,45,51)/t33-,34+ | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
UniProtKB/TrEMBL
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Inhibition of CYP2C9 (unknown origin) |
J Med Chem 57: 4661-76 (2014)
Article DOI: 10.1021/jm5001216
BindingDB Entry DOI: 10.7270/Q2708302 |
More data for this
Ligand-Target Pair | |
Search and Browse
